Liraglutide news and clinical trials

A meta-analysis of 23 randomized controlled trials involving 1,723 participants found that liraglutide significantly reduced systolic blood pressure and improved various renal and metabolic biomarkers in patients with type 2 diabetic nephropathy.

Researchers conducted a randomized, blinded, placebo-controlled trial finding that Liraglutide did not improve stimulated C-peptide levels in 18 adults with long-standing type 1 diabetes after 52 weeks. Exploratory analyses suggested a steeper decline in C-peptide with Liraglutide than placebo.

New systematic review in Journal of endocrinological investigation: Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.

The FDA announced the availability of additional revised draft product-specific guidances. These documents provide recommendations for industry on designing bioequivalence studies to support abbreviated new drug applications.

The Affiliated Nanjing Drum Tower Hospital completed a randomized controlled trial of 396 participants evaluating the effects of Liraglutide, Empagliflozin, and Linagliptin on cognitive function in patients with Type 2 Diabetes and mild cognitive impairment.

The FDA is extending the comment period for a notice concerning the 503B Bulks List of drug substances. This follows the agency's proposal not to include semaglutide, tirzepatide, or liraglutide on the list of bulk drug substances allowed for use in compounding.

A secondary analysis of the S-LiTE trial involving 130 adults showed that exercise, both alone and combined with liraglutide, improved vascular health and inflammation markers, whereas liraglutide alone did not provide these improvements.

Researchers re-analyzed the Liraglutide Effect and Action in Diabetes trial using contemporary methods and found that accounting for sustained treatment exposure produced results consistent with the original study's findings regarding cardiovascular outcomes.

Lupin Pharmaceuticals Inc. initiated a nationwide recall of 217,621 pen injectors of Liraglutide Injection. The recall was issued due to the presence of particulate matter identified as a white thread-like structure inside the cartridge.

Researchers randomized 28 patients to risk factor modification and 31 to risk factor modification plus liraglutide for 3 months before AF ablation. The liraglutide group had 81% freedom from AF at 1 year compared to 54% for the risk factor modification group.

A post hoc analysis of the LAMP trial involving 510 patients found that liraglutide significantly reduced stroke recurrence and vascular events only in patients with insulin resistance defined by a homeostasis model assessment score of 2.5 or greater.

The University of Sao Paulo General Hospital registered a phase 4 randomized controlled trial to evaluate the metabolic and cardiovascular effects of Liraglutide in 30 children aged 6 to 12 years with severe obesity.

New randomized trial in Wiadomosci lekarskie (Warsaw, Poland : 1960): Six-month effects of liraglutide and dapagliflozin on lipid profile, cardiovascular risk, and NT-proBNP levels in patients with metabolic dysfunction-associated steatotic liver disease.

The FDA announced it is proposing not to include semaglutide, tirzepatide, and liraglutide on the list of bulk drug substances for which there is a clinical need for outsourcing facilities to use in compounding. The agency is currently evaluating substances nominated for this list.

The University of Chicago suspended a phase 1 study of Liraglutide in 30 obese participants with neurocognitive deficits due to a pending study amendment.

New systematic review in Advances in therapy: Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials.

The FDA approved an application from Biocon Pharma for a liraglutide product on March 11, 2026.

The FDA approved an application from Biocon Pharma for a liraglutide product on February 24, 2026.

The FDA approved an application from Orbicular for a liraglutide product on February 24, 2026.

The GRADE Study Group posted results for a comparative effectiveness trial involving 7850 participants with Type 2 Diabetes, which compared the effectiveness of adding glimepiride, sitagliptin, liraglutide, or glargine to metformin treatment.

Centre Hospitalier Universitaire Dijon terminated a trial investigating the effect of Liraglutide on dietary preferences and habits in patients with type 2 diabetes. The study was stopped because of an exploratory protocol, convincing results, and robust analysis.

Centre Hospitalier Universitaire Dijon terminated a trial investigating the effect of Liraglutide on fatty liver content and lipoprotein metabolism in patients with type 2 diabetes. The study was stopped due to a failure of inclusion.

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School registered a completed trial examining weight loss outcomes when using Liraglutide injections at different intervals after metabolic surgery for obese patients.

New randomized trial in Diabetes research and clinical practice: Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover….

Novo Nordisk A/S posted results from a completed study comparing the effectiveness of Semaglutide 2.4 mg to other weight management medications, including Liraglutide, among 500 participants with obesity.

New meta-analysis in Diabetes, obesity & metabolism: Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis.

A double-blind, crossover trial of 20 adults found that 5 weeks of daily 3 mg liraglutide modulated 124 proteins, uniquely suppressing myostatin and vascular remodeling pathways. These proteomic changes were largely independent of weight loss.

A systematic review of 41 randomized controlled trials identified a critical evidence gap, finding that only 2 out of 41 studies assessed or reported dietary intake changes alongside the prescription of liraglutide, semaglutide, or tirzepatide.

Beni-Suef University completed a Phase 3 trial comparing the hormonal, metabolic, and clinical effects of liraglutide and metformin in 183 obese women with polycystic ovary syndrome.

Göteborg University completed an observational study of 128 children and adolescents to examine how pharmacological treatment with Liraglutide affects BMI and metabolic markers in clinical practice.

The Fourth Affiliated Hospital of Zhejiang University School of Medicine registered a study to compare weight loss outcomes in 120 overweight or obese patients using Liraglutide monotherapy versus a combination of Liraglutide and Orlistat.

Göteborg University completed a retrospective observational study of 128 children and adolescents to analyze the effects of Liraglutide on BMI trajectories and metabolic markers in routine clinical care.

New randomized trial in Frontiers in endocrinology: Combination metformin and liraglutide in PCOS: clinical efficacy in women and preclinical insights from gut microbiome modulation in rats.

The FDA announced the availability of new and revised draft product-specific guidances. These guidances offer industry recommendations on the design of bioequivalence studies for abbreviated new drug applications.

New meta-analysis in Diabetes, obesity & metabolism: Efficacy and safety of liraglutide in non-alcoholic fatty liver disease with or without type 2 diabetes: A systematic review and meta-analysis.

A phase 2b randomized clinical trial of 204 participants with mild to moderate Alzheimer's disease found no significant difference in cerebral glucose metabolism between liraglutide and placebo groups after 52 weeks. Cognitive assessments showed mixed results with limited clinical benefit.

Researchers conducted a randomized controlled trial of 20 adults with type 2 diabetes and found that 18 days of liraglutide treatment reduced total body mass and regional trunk and android fat. The study noted improvements in glycaemia but no measurable changes in lean or bone tissue.

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. registered a recruiting trial to evaluate the efficacy and safety of a triple combination therapy involving Metformin, SGLT-2i, and GLP-1RA, including Liraglutide, in patients with type 2 diabetes.

Kaiser Permanente posted results from an observational study comparing different pharmacotherapy regimens, including Liraglutide, for 241,981 patients with type 2 diabetes and cardiovascular disease to identify effects on heart health.

Novo Nordisk A/S is recruiting 71 participants for a phase 1 trial to investigate how fasting duration and withholding GLP-1 receptor agonist medications affect retained gastric contents in patients using liraglutide or semaglutide.

A randomized clinical trial of 636 patients found that adding liraglutide to standard therapy for 90 days significantly reduced stroke recurrence in patients with type 2 diabetes and minor ischemic stroke or transient ischemic attack. Patients also achieved better functional outcomes.

A meta-analysis of 7 trials including 575 patients evaluated liraglutide for weight management in children and adolescents. The drug significantly reduced body mass index, BMI z-score, body weight, HbA1c, fasting plasma glucose, and systolic blood pressure compared to placebo.

New randomized trial in JAMA network open: Liraglutide and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Randomized Clinical Trial.

A systematic review published in The Cochrane database of systematic reviews analyzed 24 randomized controlled trials involving 9937 participants to assess the effects of liraglutide on adults with obesity. The review included studies with follow-ups of at least six months.